ActivePhase 2Phase 3ACTRN12605000599673
RAD in the Treatment of Pulmonary Fibrosis
An investigator driven, randomised, placebo controlled, double blind, multi-centre study to assess the safety and efficacy of RAD (Everolimus) in the treatment of pulmonary fibrosis
Sponsor
Dr Monique Malouf
Enrollment
120 participants
Start Date
Aug 10, 2002
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 YearssMax Age: 75 Yearss
Plain Language Summary
Simplified for easier understanding
This study tests a new treatment (RAD) for pulmonary fibrosis, a condition where the lungs become scarred and breathing becomes difficult. It is open to adults aged 18 to 75 who have been diagnosed with pulmonary fibrosis. Participants would take the study medication and attend regular lung function tests.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RAD 4mg po Bd
RAD 4mg po Bd
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000599673
Related Trials
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
NCT072297161 location
Advanced Imaging for Pulmonary Fibrosis
NCT065320711 location
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401152 locations
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
NCT074641321 location